VivoSeq
Other

Older Patients

2

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Older Patients is an early-stage landscape with 2 programs across 3 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Karyopharm Therapeutics Inc, Cornerstone Pharmaceuticals. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

73/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

ApprovedK

Karyopharm Therapeutics Inc

0 programs

PreclinicalC

Cornerstone Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed8 · 47%
Unknown status3 · 18%
Terminated3 · 18%
Active, not recruiting2 · 12%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Active, not recruiting·UUniversity of Rochester·Phase 2·NCT04594798·39 enrolled
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Active, not recruiting·—·Phase 2·NCT04668885·13 enrolled
Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
Not yet recruiting·—·Phase 1/2·NCT06431932·60 enrolled
Selinexor (KPT-330) in Older Patients With Relapsed AML
Completed·KKaryopharm Therapeutics Inc·Phase 2·NCT02088541·317 enrolled
Lomustine and Intermediate Dose Cytarabine in Older Patients With AML
Completed·FFrench Innovative Leukemia Organisation·Phase 3·NCT00480064·360 enrolled
Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
Completed·GGoethe University·Phase 2·NCT03480438·52 enrolled
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
Completed·TThe Lymphoma Academic Research Organisation·Phase 3·NCT01865110·623 enrolled
Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin
Completed·UUniversity Hospital, Bordeaux·N/A·NCT02486341·30 enrolled
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00839982·35 enrolled
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01141725·39 enrolled
Effect of Sedation With Dexmedetomidine-esketamine Combination on Delirium in Postoperative ICU Patients: a Randomized Controlled Pilot Trial
Completed·PPeking University First Hospital·Approved·NCT07151716·100 enrolled
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Terminated·PPolaris Group·Phase 1·NCT02875093·23 enrolled
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Terminated·CCornerstone Pharmaceuticals·Phase 3·NCT03504410·200 enrolled
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
Terminated·WWeill Medical College of Cornell University·Phase 2·NCT02532010·13 enrolled
Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response
Unknown status·RReproductive & Genetic Hospital of CITIC-Xiangya·N/A·NCT04178135·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)